These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria. Skander D; Allenova A; Maurer M; Kolkhir P Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030 [No Abstract] [Full Text] [Related]
5. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab. MacGlashan D; Saini S; Schroeder JT J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077 [TBL] [Abstract][Full Text] [Related]
6. [HOW PERIPHERAL BASOPHILS IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA ARE CHANGED WITH OMALIZUMAB TREATMENT?]. Oda Y; Washio K; Mizuno M; Imamura S; Nishigori C; Fukunaga A Arerugi; 2021; 70(9):1196-1199. PubMed ID: 34759084 [No Abstract] [Full Text] [Related]
7. Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria. Oda Y; Fukunaga A; Washio K; Imamura S; Mizuno M; Hatakeyama M; Ogura K; Nishigori C J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1166-1176.e8. PubMed ID: 32898709 [TBL] [Abstract][Full Text] [Related]
8. A very low number of circulating basophils is predictive of a poor response to omalizumab in chronic spontaneous urticaria. Rijavec M; Košnik M; Koren A; Kopač P; Šelb J; Vantur R; Kogovšek Ž; Bizjak M; Bajrović N; Zidarn M; Korošec P Allergy; 2021 Apr; 76(4):1254-1257. PubMed ID: 32876979 [No Abstract] [Full Text] [Related]
9. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients. Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723 [TBL] [Abstract][Full Text] [Related]
10. Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria. Saini SS; Omachi TA; Trzaskoma B; Hulter HN; Rosén K; Sterba PM; Courneya JP; Lackey A; Chen H J Invest Dermatol; 2017 Apr; 137(4):958-961. PubMed ID: 27939380 [No Abstract] [Full Text] [Related]
12. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab. Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792 [No Abstract] [Full Text] [Related]
13. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count. Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504 [TBL] [Abstract][Full Text] [Related]
14. Basophil count is a sensitive marker for clinical progression in a chronic spontaneous urticaria patient treated with omalizumab. Kishimoto I; Kambe N; Ly NTM; Nguyen CTH; Okamoto H Allergol Int; 2019 Jul; 68(3):388-390. PubMed ID: 30792119 [No Abstract] [Full Text] [Related]
15. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems. Sánchez J; Alvarez L; López JF Actas Dermosifiliogr; 2024 Jan; 115(1):T88-T90. PubMed ID: 37871896 [No Abstract] [Full Text] [Related]
16. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems. Sánchez J; Alvarez L; López JF Actas Dermosifiliogr; 2024 Jan; 115(1):88-90. PubMed ID: 36754254 [No Abstract] [Full Text] [Related]
17. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy. Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277 [TBL] [Abstract][Full Text] [Related]
18. Basophil FcɛRI expression is linked to time to omalizumab response in chronic spontaneous urticaria. Deza G; Bertolín-Colilla M; Sánchez S; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM J Allergy Clin Immunol; 2018 Jun; 141(6):2313-2316.e1. PubMed ID: 29518420 [No Abstract] [Full Text] [Related]